camptothecin has been researched along with telatinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
1 trial(s) available for camptothecin and telatinib
| Article | Year |
|---|---|
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |